Latin America: How Regulatory Transparency Can Tackle Non-Comparable Biologics
Executive Summary
Non-comparable biologics are a common problem in Latin America as they could deter companies with true biosimilars from entering the market. Among the solutions are better regulatory transparency and action to deal with “non-comparables” already on the market, says FIFARMA, the Latin American Federation of Pharmaceutical Industry.